Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common stock, $0.001 par value per share
-
Shares outstanding
-
13M
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
9.91M
-
Shares change
-
-534K
-
Total reported value, excl. options
-
$55.5M
-
Value change
-
-$2.73M
-
Put/Call ratio
-
0
-
Number of buys
-
23
-
Number of sells
-
-69
-
Price
-
$5.60
Significant Holders of Eagle Pharmaceuticals, Inc. - Common stock, $0.001 par value per share (EGRX) as of Q2 2024
108 filings reported holding EGRX - Eagle Pharmaceuticals, Inc. - Common stock, $0.001 par value per share as of Q2 2024.
Eagle Pharmaceuticals, Inc. - Common stock, $0.001 par value per share (EGRX) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.91M shares
of 13M outstanding shares and own 76.29% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (1.96M shares), AIGH Capital Management LLC (1.21M shares), CITIGROUP INC (1M shares), AQR CAPITAL MANAGEMENT LLC (697K shares), VANGUARD GROUP INC (564K shares), BlackRock Inc. (353K shares), BANK OF AMERICA CORP /DE/ (326K shares), MORGAN STANLEY (300K shares), LSV ASSET MANAGEMENT (295K shares), and RENAISSANCE TECHNOLOGIES LLC (244K shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.